Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections

Michael Halpern, Mary A. Cifaldi, Jordana K. Schmier

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We used decision-analysis modeling to compare costs and outcomes of clarithromycin extended-release (Biaxin XL, Abbott Laboratories, Abbott Park, Illinois, USA) and clarithromycin immediate-release (Biaxin, Abbott Laboratories, Abbott Park, Illinois, USA) for outpatients with lower respiratory tract infections (LRTI). More patients achieved clinical cure with extended-release (83.9%) versus immediate-release (72.8%); fewer discontinued due to adverse events. Total costs with extended-release were $32 (16%) less; incorporating greater adherence for extended-release (once-daily) therapy resulted in greater savings. Results indicate that clarithromycin extended-release is cost-saving compared with immediate-release for LRTI.

Original languageEnglish (US)
Pages (from-to)217-223
Number of pages7
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Volume2
Issue number2
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Clarithromycin
Respiratory Tract Infections
Costs and Cost Analysis
Decision Support Techniques
Outpatients

Keywords

  • Bronchitis
  • Chronic
  • Clarithromycin
  • Costs and cost analysis
  • Economic
  • Models
  • Pneumonia
  • Respiratory tract infections

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections. / Halpern, Michael; Cifaldi, Mary A.; Schmier, Jordana K.

In: COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 2, No. 2, 2005, p. 217-223.

Research output: Contribution to journalArticle

@article{d789fe6f409c4f5086376a14a38d7adb,
title = "Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections",
abstract = "We used decision-analysis modeling to compare costs and outcomes of clarithromycin extended-release (Biaxin XL, Abbott Laboratories, Abbott Park, Illinois, USA) and clarithromycin immediate-release (Biaxin, Abbott Laboratories, Abbott Park, Illinois, USA) for outpatients with lower respiratory tract infections (LRTI). More patients achieved clinical cure with extended-release (83.9{\%}) versus immediate-release (72.8{\%}); fewer discontinued due to adverse events. Total costs with extended-release were $32 (16{\%}) less; incorporating greater adherence for extended-release (once-daily) therapy resulted in greater savings. Results indicate that clarithromycin extended-release is cost-saving compared with immediate-release for LRTI.",
keywords = "Bronchitis, Chronic, Clarithromycin, Costs and cost analysis, Economic, Models, Pneumonia, Respiratory tract infections",
author = "Michael Halpern and Cifaldi, {Mary A.} and Schmier, {Jordana K.}",
year = "2005",
doi = "10.1081/COPD-200057588",
language = "English (US)",
volume = "2",
pages = "217--223",
journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",
issn = "1541-2555",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections

AU - Halpern, Michael

AU - Cifaldi, Mary A.

AU - Schmier, Jordana K.

PY - 2005

Y1 - 2005

N2 - We used decision-analysis modeling to compare costs and outcomes of clarithromycin extended-release (Biaxin XL, Abbott Laboratories, Abbott Park, Illinois, USA) and clarithromycin immediate-release (Biaxin, Abbott Laboratories, Abbott Park, Illinois, USA) for outpatients with lower respiratory tract infections (LRTI). More patients achieved clinical cure with extended-release (83.9%) versus immediate-release (72.8%); fewer discontinued due to adverse events. Total costs with extended-release were $32 (16%) less; incorporating greater adherence for extended-release (once-daily) therapy resulted in greater savings. Results indicate that clarithromycin extended-release is cost-saving compared with immediate-release for LRTI.

AB - We used decision-analysis modeling to compare costs and outcomes of clarithromycin extended-release (Biaxin XL, Abbott Laboratories, Abbott Park, Illinois, USA) and clarithromycin immediate-release (Biaxin, Abbott Laboratories, Abbott Park, Illinois, USA) for outpatients with lower respiratory tract infections (LRTI). More patients achieved clinical cure with extended-release (83.9%) versus immediate-release (72.8%); fewer discontinued due to adverse events. Total costs with extended-release were $32 (16%) less; incorporating greater adherence for extended-release (once-daily) therapy resulted in greater savings. Results indicate that clarithromycin extended-release is cost-saving compared with immediate-release for LRTI.

KW - Bronchitis

KW - Chronic

KW - Clarithromycin

KW - Costs and cost analysis

KW - Economic

KW - Models

KW - Pneumonia

KW - Respiratory tract infections

UR - http://www.scopus.com/inward/record.url?scp=22244432141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22244432141&partnerID=8YFLogxK

U2 - 10.1081/COPD-200057588

DO - 10.1081/COPD-200057588

M3 - Article

C2 - 17136948

AN - SCOPUS:22244432141

VL - 2

SP - 217

EP - 223

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

SN - 1541-2555

IS - 2

ER -